Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Submits Riquent Application For Lupus In EU

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.

You may also be interested in...



La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus

NDA could be submitted this year, company says.

La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus

NDA could be submitted this year, company says.

La Jolla Pulls Riquent EU Marketing Application Due To Clinical Data Needs

Lupus renal disease treatment is still “approvable” in the U.S. pending submission of additional data to FDA.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel